TaiMed Biologics (ROCO:4147) FCF Margin % : 23.71% (As of Mar. 2025)

View and export this data going back to 2010. Start your Free Trial

What is TaiMed Biologics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. TaiMed Biologics's Free Cash Flow for the three months ended in Mar. 2025 was NT$41.8 Mil. TaiMed Biologics's Revenue for the three months ended in Mar. 2025 was NT$176.2 Mil. Therefore, TaiMed Biologics's FCF Margin % for the quarter that ended in Mar. 2025 was 23.71%.

As of today, TaiMed Biologics's current FCF Yield % is -1.56%.

The historical rank and industry rank for TaiMed Biologics's FCF Margin % or its related term are showing as below:

ROCO:4147' s FCF Margin % Range Over the Past 10 Years
Min: -9463.94 Med: -108.34 Max: -6.46
Current: -63.16

During the past 13 years, the highest FCF Margin % of TaiMed Biologics was -6.46%. The lowest was -9463.94%. And the median was -108.34%.

ROCO:4147's FCF Margin % is ranked better than
54.65% of 999 companies
in the Biotechnology industry
Industry Median: -102.06 vs ROCO:4147: -63.16

TaiMed Biologics FCF Margin % Historical Data

The historical data trend for TaiMed Biologics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TaiMed Biologics FCF Margin % Chart

TaiMed Biologics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

-81.17

-54.38

-108.34

-6.46

-65.38

TaiMed Biologics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
FCF Margin %	Get a 7-Day Free Trial															14.83	27.71	30.50	-348.78	23.71

Competitive Comparison of TaiMed Biologics's FCF Margin %

For the Biotechnology subindustry, TaiMed Biologics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TaiMed Biologics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TaiMed Biologics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where TaiMed Biologics's FCF Margin % falls into.

Save Embed

;

Save Embed

;

TaiMed Biologics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

TaiMed Biologics's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-398.904	/	610.162
	=	-65.38 %

TaiMed Biologics's FCF Margin for the quarter that ended in Mar. 2025 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2025 )	/	Revenue (Q: Mar. 2025 )
	=	41.781	/	176.241
	=	23.71 %

TaiMed Biologics FCF Margin % Related Terms

Thank you for viewing the detailed overview of TaiMed Biologics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

TaiMed Biologics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TaiMed Biologics Inc (ROCO:4147) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 607, Ruiguang Road, 3rd Floor, Neihu District, Taipei, TWN, 11492

Website

https://www.taimedbiologics.com

TaiMed Biologics Inc is a biotechnology company committed to have the expertise and capability in developing, manufacturing and commercializing new drugs for the treatment and prevention of infectious diseases. Its products include Trogarzo IV Infusion, Trogarzo IV Push, TMB-365, TMB-365/TMB-380 (TMB-365 and TMB-380 combination), and Antibody-Drug Conjugates, ADCs.

TaiMed Biologics Headlines

No Headlines